Lexaria Bioscience price to sales ratio LEXX

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 26.2×
6-year median: 41.0×
Against its 6-year history: 12th; percentile: 0 is its lowest day, 100 its highest
6-year range: 12.1× to 121×
Peer median: 1.4×

Lexaria Bioscience's price to sales ratio is 26.2× as of Oct 23, 2026.

That is below its 6-year median of 41.0×, lower than on 88% of days in the last 6 years.

Over that time it ranged from 12.1× in Jun 2023 to 121× in Sep 2026.

The median for 10 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.2×	20.6×	121×
2025	16.7×	16.7×	86.1×
2024	86.1×	40.7×	89.1×
2023	37.7×	12.1×	64.5×
2022	57.3×	34.5×	111×
2021	31.9×	31.9×	59.5×

Against its peers

Companies in Healthcare nearest Lexaria Bioscience's size, closest first, today.

Company	Price to sales ratio
LEXXLexaria Bioscience	26.2×
OXBROXBRIDGE RE HOLDINGS	2.8×
EDUCEducational Development	0.4×
GTIMGood Times Restaurants	0.1×
MDRRMedalist Diversified	1.6×
BCGBinah Capital	0.1×
VIPVulcan Infrastructure & Power	0.4×
MXCMexco Energy	3.0×
CKXCKX Lands	31.0×
MSGMMotorsport Games	1.5×
ATCHAtlasClear	1.2×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Lexaria Bioscience

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.